December 15, 2020

Epeleuton and the potential of next generation Omega-3 fatty acids is discussed in the December 2020 edition of Pharmaceutical Market Europe

The article can be found below.   Treatment and prevention of cardiovascular disease The potential of next generation omega-3 fatty acids In 2019 approximately 17.3 million […]
August 11, 2020

Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers

The Epeleuton Phase 2a data was accepted for publication in the peer reviewed Journal of the American Heart Association. The paper can be found here. In […]